| Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. | |
| | |
MedLine Citation:
|
PMID: 9636014 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to evaluate the antitumor activity of vinorelbine and oral estramustine phosphate in patients with metastatic, hormone-refractory prostate cancer. We evaluated the activity of this association using the following schedule: estramustine phosphate 600 mg/m2/day orally days 1-42 and vinorelbine 25 mg/m1 days 1, 8, 22, 29 cycles repeated every 56 days. Twenty-five patients were included in the study, 24 being evaluable for response and 25 for toxicity. Out of 5 patients with measurable disease, none had an objective response. Of the 24 assessable patients with bone metastases, 9 patients had a > or = 65% decline in pretreatment prostate-specific antigen (PSA) level, stable disease was observed in 10 and 5 patients progressed. Toxicities were minimal. Anemia was observed in 5 patients, alopecia in 4 and nausea and vomiting was observed in 6 patients. Anorexia and weight loss of more than 10% were observed in 2 patients. This combination is active and well tolerated in hormone-resistant prostate cancer. These results support the therapeutic strategy of combining agents that impair microtubule function. |
| | |
Authors:
|
J Carles; M Domenech; A Gelabert-Mas; M Nogue; J M Tabernero; A Arcusa; I Guasch; A Miguel; J J Ballesteros; X Fabregat |
Related Documents
:
|
3887894 - Differences in cea values determined by eia and ria in patients with benign and maligna... 12664064 - Role of ca 15-3 in patients with biochemically suspected prostate cancer and multiple n... 15126814 - Granulomatous prostatitis linked to hla-drb1*1501. 10629644 - Comparison of cea, mca, ca 15-3 and ca 27-29 in follow-up and monitoring therapeutic re... 17000974 - First seizure presentation: do multiple seizures within 24 hours predict recurrence? 2818284 - Simple microphthalmos. |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Acta oncologica (Stockholm, Sweden) Volume: 37 ISSN: 0284-186X ISO Abbreviation: Acta Oncol Publication Date: 1998 |
Date Detail:
|
Created Date: 1998-07-02 Completed Date: 1998-07-02 Revised Date: 2009-05-12 |
Medline Journal Info:
|
Nlm Unique ID: 8709065 Medline TA: Acta Oncol Country: NORWAY |
Other Details:
|
Languages: eng Pagination: 187-91 Citation Subset: IM |
Affiliation:
|
Uro-Oncology Unit, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Spain. 90604@imas.imim.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
mortality,
secondary Administration, Oral Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Drug Administration Schedule Estramustine / administration & dosage, adverse effects Humans Male Middle Aged Prostatic Neoplasms / drug therapy*, mortality, pathology Survival Rate Vinblastine / administration & dosage, adverse effects, analogs & derivatives |
| Chemical | |
Reg. No./Substance:
|
2998-57-4/Estramustine; 71486-22-1/vinorelbine; 865-21-4/Vinblastine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Growth hormone reduces mortality and bacterial translocation in irradiated rats.
Next Document: Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas.